| Turbine–Accel: investment, 202101 financing round pre-Series A totalling €5.7m incl new + lead investor Accel |
2021-01-07 |
| TTP Group–Battery Ventures: investment, 201810 acquisition €na of TTP Labtech from TTP Group by Battery Ventures |
2018-09-27 |
| TrueMass–Scott Partnership: public relations, 202110 service existent by Scott PR |
2021-10-26 |
| TrueMass–OTHER: investment, 2020– significant seed funding from business angels |
2020-01-01 |
| Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek |
2020-06-04 |
| Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek |
2020-06-04 |
| Tropic Biosciences–SEVERAL: investment, 2018 financing round Series A approx $10m co-led by Pontifax AgTech + Five Seasons Ventures |
2018-01-01 |
| Tropic Biosciences–Pontifax: investment, 2018 financing round Series A approx totalling $10m incl co-lead investor Pontifax AgTech |
2018-01-01 |
| Tropic Biosciences–Five Seasons Ventures: investment, 2018 financing round Series A approx totalling $10m incl co-lead investor Five Seasons Ventures |
2018-01-01 |
| Trio Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in China by Trio Biotech Co Ltd |
2019-10-09 |
| Tridek-One–SEVERAL: investment, 202209 2nd financing round €16m led by Pureos Bioventures |
2022-09-15 |
| Tridek-One–SEVERAL: investment, 201906 1st financing round €3m with AFB (AdBio Partners) + Advent Life Sciences |
2019-06-04 |
| Tridek-One–Advent Life Sciences: investment, 202209 2nd financing round totalling €16m incl existing + co-investor Advent Life Sciences |
2022-09-15 |
| Tridek-One–Advent Life Sciences: investment, 201906 1st financing round totalling €3m incl investor Advent Life Sciences |
2019-06-04 |
| Treos Bio–SEVERAL: investment, 201702 private financing round $8m incl BXR Partners LLP |
2017-02-13 |
| TreeFrog Therapeutics–Andrew Lloyd Associates: public relations, 201905 service existent by ALA |
2019-05-13 |
| Transition Bio–SEVERAL: investment, 202206 financing round Series A $50m led by Northpond Ventures |
2022-06-02 |
| Transine Therapeutics–Takeda: investment, 202106 seed financing round totalling £9.1m incl co-lead investor Takeda Ventures |
2021-06-02 |
| Transine Therapeutics–SV Health Investors: investment, 202205 seed financing round expansion totalling £4.6m incl existing + co-investor DDF |
2022-05-31 |
| Transine Therapeutics–SV Health Investors: investment, 202106 seed financing round totalling £9.1m incl co-lead investor Dementai Discovery Fund |
2021-06-02 |
| Transine Therapeutics–SEVERAL: investment, 202205 seed financing round expansion £4.6m led by Epidarex bringing total seed round to £13.7m |
2022-05-31 |
| Transine Therapeutics–SEVERAL: investment, 202106 seed financing round £9.1m co-led by Takeda Ventures + Dementia Discovery Fund |
2021-06-02 |
| Transine Therapeutics–Huntsworth: public relations, 202106 service existent by Citigate Dewe Rogerson |
2021-06-02 |
| Transine Therapeutics–Epidarex Capital: investment, 202205 seed financing round expansion totalling £4.6m incl new + lead investor Epidarex |
2022-05-31 |
| Transgene–Huntsworth: public relations, 201905 service existent by Citigate Dewe Rogerson |
2019-05-02 |
| TrakCel–SEVERAL: investment, 202103 financing round co-led by AmerisourceBergen + LabCorp |
2021-03-03 |
| TrakCel–LabCorp: investment, 202103 financing round co-led by strategic investor LabCorp |
2021-03-03 |
| TrakCel–Image Box: public relations, 201709 supply service existent by Image Box PR |
2017-09-07 |
| TrakCel–AmerisourceBergen: investment, 202103 financing round co-led by strategic investor AmerisourceBergen |
2021-03-03 |
| Touchlight–SEVERAL: investment, 202109 financing round extension £50m bringing total round to £92m led by Bridford + Novator |
2021-09-15 |
| Touchlight–SEVERAL: investment, 202103 financing round £42m led by Bridford Investments Ltd |
2021-03-11 |
| Touchlight–Novator Partners: investment, 202109 financing round extension £50m incl co-lead investor Novator Partners |
2021-09-15 |
| Touchlight–Instinctif Partners: public relations, 202103 service existent by Instinctif |
2021-03-11 |
| Touchlight–Gates Foundation: grant, 202211– grant to advance pre-clinical development of doggybone DNA vaccine platform |
2022-11-29 |
| Touchlight–Bridford Group: investment, 202109 financing round extension £50m incl co-lead investor Bridford Investments Ltd |
2021-09-15 |
| Touchlight–Bridford Group: investment, 202103 financing round totalling £42m incl lead investor Bridford Investments Ltd |
2021-03-11 |
| Torreya–Stifel: investment, 202212– acquisition €na of Torreya Partners LLC by Stifel ANNOUNCED |
2022-12-22 |
| Topas Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €18m bringing total round to €40m incl all existing investors |
2021-07-29 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202107 financing round Series B extension €18m incl existing investor Epidarex Capital |
2021-07-29 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–EMBL: investment, 202107 financing round Series B extension €18m incl existing investor EMBL Ventures |
2021-07-29 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201 |
2017-01-04 |
| Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
| ThromboGenics–Bicycle Therapeutics: small-molecule drugs, 201805– collab expansion RnD of bicycle peptides for eye diseases |
2018-05-25 |
| ThromboGenics–Bicycle Therapeutics: small-molecule drugs, 201704 collab existent RnD of bicycle peptides for eye diseases |
2017-04-20 |
| Thrive Earlier Detection–Exact Sciences: investment, 202010– acquisition $1.7b upfront with 35% in cash + 65% common stock plus $450m milestones |
2020-10-26 |
| TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine |
2020-01-01 |
| Thermo Fisher–ERS Genomics: CRISPR technology, 201809– license ww non-excl rights to products + tools + services for research from ERS Genomics |
2018-09-18 |
| Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata |
2018-08-27 |
| Theragnostics–Optimum Strategic Communications: public relations, 201909 service existent by Optimum |
2019-09-05 |
| Theragnostics–Memorial Sloan-Kettering: radioPARP inhibitor, 201902– license of rPARPi for developm as cancer theragnostic |
2019-02-28 |
| Theragnostics–AstraZeneca: PARP inhibitors, 201909– license ww freedom to operate for developm of rPARPi as cancer theragnostic |
2019-09-05 |
| Theragnostics–Ariceum Therapeutics: investment, 202306 acquisition 100% of Theragnostics Ltd for $2.5m cash upfront plus $41.5m milestones |
2023-06-01 |
| Theolytics–Univ Oxford: investment, 202404 financing round totalling £19m incl existing investor Univ Oxford |
2024-04-17 |
| Theolytics–Univ Oxford: investment, 202107 financing round Series A expansion incl existing investor Univ Oxford |
2021-07-08 |
| Theolytics–Univ Oxford: investment, 202101 financing round Series A totalling £5m incl existing + co-investor OSI |
2021-01-07 |
| Theolytics–Univ Oxford: investment, 201906 emerges from stealth with £2.5m seed investment from OSI |
2019-06-26 |
| Theolytics–United Kingdom (govt): grant, 202011–202204 Innovate UK Smart Fund grant to develop TheoAd281 for ovarian cancer |
2020-11-01 |
| Theolytics–Sound Bioventures: investment, 202404 financing round totalling £19m incl new investor Sound Bioventures |
2024-04-17 |
| Theolytics–SEVERAL: investment, 202404 financing round £19m incl new investor Sound Bioventures |
2024-04-17 |
| Theolytics–SEVERAL: investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–SEVERAL: investment, 202101 financing round Series A £5m co-led by Epidarex Capital + Taiho Ventures |
2021-01-07 |
| Theolytics–Scius Communications: public relations, 202101 supply service existent by Scius Communications |
2021-01-07 |
| Theolytics–Oxford Science Enterprises: investment, 202404 financing round totalling £19m incl existing investor Oxford Science Enterprises |
2024-04-17 |
| Theolytics–Otsuka: investment, 202404 financing round totalling £19m incl existing investor Taiho Ventures |
2024-04-17 |
| Theolytics–Otsuka: investment, 202107 financing round Series A expansion incl existing investor Taiho Ventures |
2021-07-08 |
| Theolytics–Otsuka: investment, 202101 financing round Series A totalling £5m incl new + co-lead investor Taiho Ventures LLC |
2021-01-07 |
| Theolytics–Merck (DE): investment, 202404 financing round totalling £19m incl existing investor M Ventures |
2024-04-17 |
| Theolytics–Merck (DE): investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–Epidarex Capital: investment, 202404 financing round totalling £19m incl existing investor Epidarex Capital |
2024-04-17 |
| Theolytics–Epidarex Capital: investment, 202101 financing round Series A totalling £5m incl new + co-lead investor Epidarex Capital |
2021-01-07 |
| Tesaro–Teneobio: antibody cancer drug, 201801– collab RnD + license using UniRat platform to generate multispecific antibodies |
2018-01-08 |
| Tesaro–GSK: investment, 201812–201901 acquisition $5.1b (£4b) in cash incl net debt assumption of Tesaro Inc by GSK |
2018-12-03 |
| Terumo–Image Box: public relations, 202204 service existent for Terumo Blood and Cell Technologies by Image Box Communications |
2022-04-13 |
| TerSera Therapeutics–AstraZeneca: goserelin, 201702 acquisition of commercial rights to Zoladex for US + CA for $250m + $70m milestones + royalties |
2017-02-20 |
| Teon Therapeutics–Cancer Research UK: small-molecule cancer drug, 202102 collab existent for development of TT-702 |
2021-02-22 |
| Tenpoint Therapeutics–Univ College London: investment, 202307 financing round Series A totalling $70m incl existing + co-investor UCL Technology Fund |
2023-07-12 |
| Tenpoint Therapeutics–United Kingdom (govt): investment, 202307 financing round Series A totalling $70m incl new + co-lead investor BPC |
2023-07-12 |
| Tenpoint Therapeutics–Sofinnova: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor Sofinnova Partners |
2023-07-12 |
| Tenpoint Therapeutics–SEVERAL: investment, 202307 financing round Series A $70m led by F-Prime Capital + Sofinnova Partners + British Patient Capital |
2023-07-12 |
| Tenpoint Therapeutics–Qiming: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Qiming Venture Partners USA |
2023-07-12 |
| Tenpoint Therapeutics–Fidelity: investment, 202307 financing round Series A totalling $70m incl existing + co-investor Eight Roads |
2023-07-12 |
| Tenpoint Therapeutics–F-Prime: investment, 202307 financing round Series A totalling $70m incl existing + co-lead investor F-Prime Capital |
2023-07-12 |
| TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces |
2024-01-30 |
| Telix–Abzena: biopharmaceuticals, 201807– supply $5.9m strategic manufacturing + bioconjugation agreement |
2018-07-02 |
| Teleflex–Arcis:Altos: nucleic acid sample preparation technology, 201810– license to Teleflex from Arcis Biotechnology |
2018-10-16 |
| Teitur Trophics–Optimum Strategic Communications: public relations, 202303 service existent by Optimum |
2023-03-14 |
| Techcomp–Scott Partnership: public relations, 201702 service existent by Scott PR for Scion Instruments |
2017-02-22 |
| Tate & Lyle–Codexis: industrial enzymes, 201904– supply + license agreem for performance enzymes used to manufacture Tasteva M Stevia Sweetener |
2019-04-30 |
| Targovax–Agenus: cancer immunotherapy, 202203– collab clinical research + supply QS-21 adjuvant for mutant KRAS cancer vaccines |
2022-03-07 |
| Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford |
2019-01-03 |
| Takeda–GammaDelta Therapeutics: T cell therapy, 201705– strategic collab $100m funding Takeda + Abingworth incl investm + option to acquire GDT |
2017-05-09 |
| Takeda–Evox Therapeutics: exosome therapeutics, 202003– collab up to $926m + tiered royalties developm for up to 5 rare disease targets |
2020-03-26 |
| Takeda–Engitix: antifibrotics, 202008– collab + license agreem up to $500m+ developm for advanced liver diseases incl NASH |
2020-08-25 |
| Takeda–Denali Therapeutics: neurological drugs, 201801– collab + option agreem for 3 drug candidates for neurodegenerative diseases |
2018-01-05 |
| Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution |
2016-11-07 |
| Takeda–AstraZeneca: alpha-synuclein antibody, 201708– collab develpm + commerc of MEDI1341 in pre-clin developm for Parkinson’s disease |
2017-08-29 |
| T-Therapeutics–SEVERAL: investment, 202311 financing round Series A £48m |
2023-11-15 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 ... 29 30 31 
Deal: Collaboration or Financing
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
